Savara Future Growth

Future criteria checks 2/6

Savara is forecast to grow earnings and revenue by 50.7% and 59.7% per annum respectively while EPS is expected to grow by 48.6% per annum.

Key information

50.7%

Earnings growth rate

48.61%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	59.7%
Future return on equity	n/a
Analyst coverage	Good
Last updated	30 May 2025

Recent future growth updates

Recent updates

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05

Earnings and Revenue Growth Forecasts

NasdaqGS:SVRA - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2027	73	-44	-68	N/A	5
12/31/2026	13	-91	-136	N/A	6
12/31/2025	N/A	-105	-124	N/A	7
3/31/2025	N/A	-102	-96	-96	N/A
12/31/2024	N/A	-96	-89	-89	N/A
9/30/2024	N/A	-83	-81	-81	N/A
6/30/2024	N/A	-75	-72	-72	N/A
3/31/2024	N/A	-64	-60	-60	N/A
12/31/2023	N/A	-55	-51	-51	N/A
9/30/2023	N/A	-49	-44	-44	N/A
6/30/2023	N/A	-43	-39	-39	N/A
3/31/2023	N/A	-40	-38	-38	N/A
12/31/2022	N/A	-38	-35	-35	N/A
9/30/2022	N/A	-39	-35	-35	N/A
6/30/2022	N/A	-39	-36	-36	N/A
3/31/2022	N/A	-41	-39	-39	N/A
12/31/2021	N/A	-43	-40	-40	N/A
9/30/2021	0	-45	-43	-43	N/A
6/30/2021	0	-46	-41	-41	N/A
3/31/2021	0	-44	-36	-36	N/A
12/31/2020	0	-50	-43	-40	N/A
9/30/2020	0	-68	-41	-37	N/A
6/30/2020	N/A	-69	-45	-42	N/A
3/31/2020	N/A	-81	-51	-47	N/A
12/31/2019	N/A	-78	-45	-45	N/A
9/30/2019	N/A	-57	-46	-46	N/A
6/30/2019	N/A	-57	-43	-43	N/A
3/31/2019	N/A	-47	-41	-40	N/A
12/31/2018	N/A	-62	N/A	-39	N/A
9/30/2018	N/A	-58	N/A	-38	N/A
6/30/2018	N/A	-52	N/A	-38	N/A
3/31/2018	N/A	-53	N/A	-35	N/A
12/31/2017	N/A	-31	N/A	-28	N/A
9/30/2017	0	-28	N/A	-21	N/A
6/30/2017	0	-25	N/A	-16	N/A
3/31/2017	0	-14	N/A	-9	N/A
12/31/2016	0	-11	N/A	-8	N/A
12/31/2015	0	-9	N/A	-5	N/A
12/31/2014	2	-6	N/A	-4	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SVRA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SVRA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SVRA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SVRA's revenue (59.7% per year) is forecast to grow faster than the US market (9% per year).

High Growth Revenue: SVRA's revenue (59.7% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if SVRA's Return on Equity is forecast to be high in 3 years time

Discover growth companies

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/07/20 01:11
End of Day Share Price	2025/07/18 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Savara Inc. is covered by 15 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Dewey Steadman	Canaccord Genuity
Liisa Bayko	Citizens JMP Securities, LLC
Jonathan Wolleben	Citizens JMP Securities, LLC

Savara Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target decreased by 11% to US$8.31

Price target increased by 8.3% to US$10.36

Price target decreased by 7.9% to US$9.93

Price target increased by 19% to US$10.71

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

Savara Inc.(NasdaqGS:SVRA) dropped from Russell 3000 Value Index

Independent Director recently bought US$99k worth of stock

Price target decreased by 11% to US$8.31

Savara Receives Refusal to File Letter from the U.S. Food and Drug Administration for the Biologics License Application

New minor risk - Profitability

New minor risk - Profitability

Savara Inc., Annual General Meeting, Jun 05, 2025

Savara: Make-It-Or-Break-It Molbreevi BLA Filing

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

Independent Director recently bought US$416k worth of stock

Price target increased by 8.3% to US$10.36

Insufficient new directors

Savara Inc. Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI as Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Savara Inc. to Present New Data from the Phase 3 IMPALA-2 Trial of Molgramostim Inhalation Solution (Molgramostim) in Patients with Autoimmune Pulmonary Alveolar Proteinosis (aPAP) at the American Thoracic Society International Conference 2025

Savara Inc. Announces U.S. Launch of the Apap Clearpath™? Dried Blood Spot Test to Detect Autoimmune Pulmonary Alveolar Proteinosis

New minor risk - Insider selling

Savara Inc. Announces Manuscript on Long-Term Outcomes with Molgramostim Inhalation Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Published in ERJ Open Research

Savara: Rolling BLA Submission Of MOLBREEVI Generates Catalysts To Track

Savara Inc. Initiates Rolling Submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* for the Potential Treatment of Autoimmune Pulmonary Alveolar Proteinosis (aPAP)

Chairman & CEO recently sold US$181k worth of stock

Chairman & CEO notifies of intention to sell stock

Independent Director recently bought US$288k worth of stock

New minor risk - Profitability

Price target decreased by 7.9% to US$9.93

New minor risk - Profitability

Savara Appoints Braden Parker as Chief Commercial Officer

Savara: Trial Successful, But I'm Only Half Convinced

Price target increased by 19% to US$10.71

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial

Savara: The Binary Bet On Phase 3 Data

Savara Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Savara Inc., Annual General Meeting, Jun 06, 2024

Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024

No longer forecast to breakeven

New minor risk - Profitability

Chairman & CEO recently sold US$396k worth of stock

Forecast to breakeven in 2026

Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

New minor risk - Profitability

No longer forecast to breakeven

Price target increased by 7.3% to US$5.50

Price target increased by 7.5% to US$5.38

New minor risk - Shareholder dilution

New minor risk - Share price stability

Savara Inc. has completed a Follow-on Equity Offering in the amount of $79.994334 million.

Savara Inc. Completes Enrollment of Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis

Independent Director recently bought US$259k worth of stock

No longer forecast to breakeven

Price target increased by 21% to US$4.60

Savara Inc. Announces New Leadership Appointments

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Independent Director recently bought US$56k worth of stock

Forecast to breakeven in 2025

Independent Director recently bought US$82k worth of stock

Independent Director recently bought US$68k worth of stock

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Independent Director recently bought US$187k worth of stock

Independent Director recently bought US$142k worth of stock

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Savara GAAP EPS of -$0.06 in-line

Independent Director recently bought US$138k worth of stock

Price target increased to US$4.50

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Independent Director recently bought US$64k worth of stock

Independent Director recently bought US$215k worth of stock

Independent Director recently bought US$176k worth of stock